Figure 1.
Levels of miR-10a and miR-10b expression are significantly increased in AML cases. (A) The expression level of miR-10a in PBMNCs derived from 89 patients with AML and 65 healthy donors detected by TaqMan quantitative polymerase chain reaction. (B) The expression level of miR-10a in different AML subtypes, from M1 to M5. (C) The expression level of miR-10a in different WHO subtypes of AML patients compared with the normal controls. (D) The expression level of miR-10a in AML patients with mutated and wild-type NPM1 compared with the normal controls. (E) The expression level of miR-10b in PBMNCs derived from 89 AML patients and 65 healthy donors. (F) The expression level of miR-10b in different AML subtypes, from M1 to M5. (G) The expression level of miR-10b in different WHO subtypes of AML patients compared with the normal controls. (H) The expression level of miR-10b in AML patients with mutated and wild-type NPM1 compared with the normal controls. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; ns, not significant. AML, acute myeloid leukemia; miR, microRNA; NPM1, nucleophosmin; PBMNC, peripheral blood mononuclear cell; WHO, World Health Organization; NPM1+, NPM1 mutated; NPM1-, wild-type NPM1.
